Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

A compound of the general formula (I)

• wherein
• independently represents a single bond or a double bond;
• the linker L is C1-10 alkylene which is optionally substituted by one or more C1-4 alkyl groups, wherein two hydrogen atoms on one carbon atom of the C1-10 alkylene group can be replaced by an oxygen atom to form a carbonyl group, provided that the linker L does not contain more than one carbonyl group;
• alternatively one CH2 can be replaced by NR, wherein R is selected from H, C1-6 alkyl, optionally substituted aryl and optionally substituted heteroaryl, C1-4 alkylene-(optionally substituted aryl) and C1-4 alkylene-(optionally substituted heteroaryl);
• alternatively the linker L is a 4 to 10-membered linking group which is substituted by two substituents which are joined together to form a saturated, unsaturated or aromatic 5- or 6-membered ring which is fused with the linking group;
• A and A′ are each independently a 5- to 7-membered heterocyclic ring, wherein the heterocyclic rings A und A′ are optionally substituted by one or more substituents, selected from C1-6 alkyl, C3-6 cycloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, C1-4 alkylene-(optionally substituted phenyl) and C1-4 alkylene-(optionally substituted heteroaryl), or two substituents may be joined to form an optionally substituted, saturated, unsaturated or aromatic 5- to 7-membered ring which is fused with the heterocyclic ring A or A′, and wherein the heterocyclic rings A und A′ may contain in addition to the units X, X′, Y and Y′ one or more heteroatoms, selected from N, NR, S and O, wherein R is selected from H and C1-4 alkyl;
• the units X and X′ are each independently a H-bond acceptor;
• and
• the units Y and Y′ are each independently a H-bond donor.